BVXV - ビオンドバックス・ファ―マス―ティカルズ (BiondVax Pharmaceuticals Ltd.) ビオンドバックス・ファ―マス―ティカルズ

 BVXVのチャート


 BVXVの企業情報

symbol BVXV
会社名 BiondVax Pharmaceuticals Ltd (ビオンドバックス・ファ―マス―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種    医療関連(Health Care)
概要 事業概要 --   ビオンドバックス・ファ―マス―ティカルズは、イスラエルのバイオ医薬品企業。感染症の免疫調節療法に焦点をあて、臨床段階の医薬品の開発および実用化に従事。製品候補M-001は合成ペプチドベ―スのタンパク質で、季節的なインフルエンザウイルスと流行性インフルエンザウイルスの両方を標的に長期的な保護を提供するよう設計、開発を行う。   
本社所在地 14 Einstein Street Ness Ziona 74036 ISR
代表者氏名
代表者役職名
電話番号
設立年月日 37803
市場名 NASDAQ Small Cap
ipoyear 2015年
従業員数
url www.biondvax.com
nasdaq_url https://www.nasdaq.com/symbol/bvxv
adr_tso 5675763
EBITDA EBITDA ー
終値(lastsale) 5.59
時価総額(marketcap) 31727515.17
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 BVXVのテクニカル分析


 BVXVのニュース

   BiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering  2021/02/10 21:30:00 Benzinga
JERUSALEM , Feb. 10, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV ), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced that the underwriter of its recent follow-on underwritten offering fully exercised its over-allotment option to purchase 365,217 of BiondVax's American Depositary Shares ("ADS"). The option was granted in connection with the follow-on offering of 2,434,783 ADSs at a public offering price of $4.95 per ADS which closed on February 2, 2020 . The exercise of the over-allotment option brings the total gross proceeds of the offering to approximately $13.8 million . Aegis Capital Corp. acted as sole bookrunning manager for the offering. The ADSs described above were offered by the Company pursuant to a registration statement that was previously filed with the Securities and Exchange Commission (the "SEC") and declared effective by the SEC on August 10, 2020 .
   BiondVax Announces Closing of $12.1 Million Follow-on Underwritten Offering  2021/02/02 21:30:00 PR Newswire
JERUSALEM, Israel, Feb. 2, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today…
   BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares  2021/01/29 12:57:00 PR Newswire
JERUSALEM, Jan. 29, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced…
   BiondVax Pharmaceuticals Earnings : What to expect Stock market Insights & financial analysis  2020/11/24 22:20:00 Stock Market Daily
BiondVax Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies  2020/11/10 13:40:14 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 9) Alcon AG (NYSE: ALC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Aptevo Therapeutics Inc (NASDAQ: APVO ) (announced second complete remission in a patient in Cohort 6 of a Phase 1 study of AVO436 in acute myeloid leukemia and myelodysplastic syndrome patients) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioLife Solutions Inc (NASDAQ: BLFS ) BioNTech SE – ADR (NASDAQ: BNTX ) - announced over 90% efficacy in the Phase 3 study of its coronavirus vaccine candidate co-developed with Pfizer Inc. (NYSE: PFE ) C4 Therapeutics Inc (NASDAQ: CCCC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) (announced positive topline results from Part A of the Phase 3 clinical trial of Nefecon in patients with primary IgA nephropathy) Catalent Inc (NYSE: CTLT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Halozyme Therapeutics, Inc.
   BiondVax Pharmaceuticals Earnings : What to expect Stock market Insights & financial analysis  2020/11/24 22:20:00 Stock Market Daily
BiondVax Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies  2020/11/10 13:40:14 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 9) Alcon AG (NYSE: ALC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Aptevo Therapeutics Inc (NASDAQ: APVO ) (announced second complete remission in a patient in Cohort 6 of a Phase 1 study of AVO436 in acute myeloid leukemia and myelodysplastic syndrome patients) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioLife Solutions Inc (NASDAQ: BLFS ) BioNTech SE – ADR (NASDAQ: BNTX ) - announced over 90% efficacy in the Phase 3 study of its coronavirus vaccine candidate co-developed with Pfizer Inc. (NYSE: PFE ) C4 Therapeutics Inc (NASDAQ: CCCC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) (announced positive topline results from Part A of the Phase 3 clinical trial of Nefecon in patients with primary IgA nephropathy) Catalent Inc (NYSE: CTLT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Halozyme Therapeutics, Inc.
   The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure  2020/11/03 12:38:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 2) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Immunovant Inc (NASDAQ: IMVT ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 2) AEterna Zentaris Inc. (NASDAQ: AEZS ) Aikido Pharma Inc (NASDAQ: AIKI ) Artelo Biosciences Inc (NASDAQ: ARTL ) Avita Therapeutics Inc (NASDAQ: RCEL ) Benitec Biopharma Inc (NASDAQ: BNTC ) BioCardia Inc (NASDAQ: BCDA ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Celsion Corporation (NASDAQ: CLSN ) Codiak BioSciences Inc (NASDAQ: CDAK ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) FSD Pharma Inc (NASDAQ: HUGE ) Galecto Inc (NASDAQ: GLTO ) (went public Thursday) Hoth Therapeutics Inc (NASDAQ: HOTH ) Inhibrx Inc (NASDAQ: INBX ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Monopar Therapeutics Inc (NASDAQ: MNPR ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) (halted dosing in Strimvelis study after it was linked to the development of leukemia in a patient) Orphazyme A S ADR (NASDAQ: ORPH ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) Stocks In Focus Aurinia Ends Dry Eye Disease Study Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) said topline results from its Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution for the potential treatment of …
   BiondVax Announces At-The-Market (ATM) Equity Offering Program  2020/10/02 10:00:00 PR Newswire
JERUSALEM, Israel, Oct. 2, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M–001 universal influenza vaccine candidate ("BiondVax" or the "Company"), today announced it has entered into an agreement with BofA Securities as lead…
   The Daily Biotech Pulse: Blueprint, Roche Ink $1.7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits  2020/07/14 12:04:55 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Altimmune Inc (NASDAQ: ALT ) (announced positive preclinical data for its intranasal vaccine candidate AdCOVID) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) (reacted to preliminary second-quarter results) Beigene Ltd (NASDAQ: BGNE ) - announced $421 million in additional investment by Amgen, Inc. (NASDAQ: AMGN ) in a $2.1-billion direct offering by the Chinese biotech BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Catalent Inc (NYSE: CTLT ) DexCom, Inc. (NASDAQ: DXCM ) Equillium Inc (NASDAQ: EQ (announced positive results for COVID-19 study of the drug it is co-developing with India's Biocon) Fulgent Genetics Inc (NASDAQ: FLGT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc.
   BiondVax Pharmaceuticals Earnings : What to expect Stock market Insights & financial analysis  2020/11/24 22:20:00 Stock Market Daily
BiondVax Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies  2020/11/10 13:40:14 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 9) Alcon AG (NYSE: ALC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Aptevo Therapeutics Inc (NASDAQ: APVO ) (announced second complete remission in a patient in Cohort 6 of a Phase 1 study of AVO436 in acute myeloid leukemia and myelodysplastic syndrome patients) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioLife Solutions Inc (NASDAQ: BLFS ) BioNTech SE – ADR (NASDAQ: BNTX ) - announced over 90% efficacy in the Phase 3 study of its coronavirus vaccine candidate co-developed with Pfizer Inc. (NYSE: PFE ) C4 Therapeutics Inc (NASDAQ: CCCC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) (announced positive topline results from Part A of the Phase 3 clinical trial of Nefecon in patients with primary IgA nephropathy) Catalent Inc (NYSE: CTLT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Halozyme Therapeutics, Inc.
   The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure  2020/11/03 12:38:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 2) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Immunovant Inc (NASDAQ: IMVT ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 2) AEterna Zentaris Inc. (NASDAQ: AEZS ) Aikido Pharma Inc (NASDAQ: AIKI ) Artelo Biosciences Inc (NASDAQ: ARTL ) Avita Therapeutics Inc (NASDAQ: RCEL ) Benitec Biopharma Inc (NASDAQ: BNTC ) BioCardia Inc (NASDAQ: BCDA ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Celsion Corporation (NASDAQ: CLSN ) Codiak BioSciences Inc (NASDAQ: CDAK ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) FSD Pharma Inc (NASDAQ: HUGE ) Galecto Inc (NASDAQ: GLTO ) (went public Thursday) Hoth Therapeutics Inc (NASDAQ: HOTH ) Inhibrx Inc (NASDAQ: INBX ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Monopar Therapeutics Inc (NASDAQ: MNPR ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) (halted dosing in Strimvelis study after it was linked to the development of leukemia in a patient) Orphazyme A S ADR (NASDAQ: ORPH ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) Stocks In Focus Aurinia Ends Dry Eye Disease Study Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) said topline results from its Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution for the potential treatment of …
   BiondVax Announces At-The-Market (ATM) Equity Offering Program  2020/10/02 10:00:00 PR Newswire
JERUSALEM, Israel, Oct. 2, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M–001 universal influenza vaccine candidate ("BiondVax" or the "Company"), today announced it has entered into an agreement with BofA Securities as lead…
   The Daily Biotech Pulse: Blueprint, Roche Ink $1.7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits  2020/07/14 12:04:55 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Altimmune Inc (NASDAQ: ALT ) (announced positive preclinical data for its intranasal vaccine candidate AdCOVID) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) (reacted to preliminary second-quarter results) Beigene Ltd (NASDAQ: BGNE ) - announced $421 million in additional investment by Amgen, Inc. (NASDAQ: AMGN ) in a $2.1-billion direct offering by the Chinese biotech BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Catalent Inc (NYSE: CTLT ) DexCom, Inc. (NASDAQ: DXCM ) Equillium Inc (NASDAQ: EQ (announced positive results for COVID-19 study of the drug it is co-developing with India's Biocon) Fulgent Genetics Inc (NASDAQ: FLGT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc.

 関連キーワード  (― 米国株 ビオンドバックス・ファ―マス―ティカルズ BVXV BiondVax Pharmaceuticals Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)